DK36492D0 - Praeparat - Google Patents

Praeparat

Info

Publication number
DK36492D0
DK36492D0 DK92364A DK36492A DK36492D0 DK 36492 D0 DK36492 D0 DK 36492D0 DK 92364 A DK92364 A DK 92364A DK 36492 A DK36492 A DK 36492A DK 36492 D0 DK36492 D0 DK 36492D0
Authority
DK
Denmark
Prior art keywords
preparation
Prior art date
Application number
DK92364A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to DK92364A priority Critical patent/DK36492D0/da
Publication of DK36492D0 publication Critical patent/DK36492D0/da
Priority to JP5516181A priority patent/JPH07504669A/ja
Priority to EP93907819A priority patent/EP0631504A1/en
Priority to PCT/DK1993/000098 priority patent/WO1993018785A1/en
Priority to AU38887/93A priority patent/AU3888793A/en
Priority to KR1019940703281A priority patent/KR950700754A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DK92364A 1992-03-19 1992-03-19 Praeparat DK36492D0 (da)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DK92364A DK36492D0 (da) 1992-03-19 1992-03-19 Praeparat
JP5516181A JPH07504669A (ja) 1992-03-19 1993-03-18 新規薬剤
EP93907819A EP0631504A1 (en) 1992-03-19 1993-03-18 Novel medicament
PCT/DK1993/000098 WO1993018785A1 (en) 1992-03-19 1993-03-18 Novel medicament
AU38887/93A AU3888793A (en) 1992-03-19 1993-03-18 Novel medicament
KR1019940703281A KR950700754A (ko) 1992-03-19 1994-09-17 신규의 약물(novel medicament)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK92364A DK36492D0 (da) 1992-03-19 1992-03-19 Praeparat

Publications (1)

Publication Number Publication Date
DK36492D0 true DK36492D0 (da) 1992-03-19

Family

ID=8092684

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92364A DK36492D0 (da) 1992-03-19 1992-03-19 Praeparat

Country Status (6)

Country Link
EP (1) EP0631504A1 (da)
JP (1) JPH07504669A (da)
KR (1) KR950700754A (da)
AU (1) AU3888793A (da)
DK (1) DK36492D0 (da)
WO (1) WO1993018785A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
BR9306551A (pt) * 1992-06-15 1998-09-15 Pfizer Derivados de peptídeo do tipo glucagona e de insulinotropina
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
DE19530865A1 (de) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1840134B1 (en) 1998-02-27 2016-04-13 Novo Nordisk A/S GLP-1 derivatives
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
EP1100530B1 (en) 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation of beta cell proliferation
KR20010073033A (ko) * 1998-08-28 2001-07-31 피터 지. 스트링거 인슐리노트로픽 펩티드의 투여 방법
EP1666054A1 (en) * 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
CA2358107C (en) * 1998-12-22 2011-08-23 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
AU2353701A (en) * 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
WO2001066135A1 (en) 2000-03-08 2001-09-13 Novo Nordisk A/S Lowering serum lipids
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
CN106137952B (zh) 2004-11-12 2020-11-17 诺和诺德公司 促胰岛素肽的稳定制剂
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
WO2007061434A2 (en) * 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
BRPI0620586A2 (pt) * 2005-12-02 2011-11-16 Nastech Pharm Co formulação farmacêutica aquosa para administração intranasal e uso de uma formulação farmacêutica aquosa para elaborar um medicamento
WO2009121804A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
TW201100104A (en) 2009-03-27 2011-01-01 Glaxo Group Ltd Drug fusions and conjugates
KR20120092611A (ko) 2009-09-30 2012-08-21 글락소 그룹 리미티드 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
EP2788027A2 (en) 2011-12-09 2014-10-15 Novo Nordisk A/S Glp-1 agonists
GB201308753D0 (en) * 2013-05-15 2013-06-26 Stichting Nl Kanker Inst Compounds and their use in therapy
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
BR112022013795A2 (pt) 2020-02-18 2022-09-13 Novo Nordisk As Composição farmacêutica líquida, e, kit

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
KR0157428B1 (ko) * 1989-02-17 1998-11-16 알렌 불룸 비 전달용 지질부형제와 그 사용법
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
DE69129226T2 (de) * 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley Glp-1-analoga verwendbar in der diabetesbehandlung

Also Published As

Publication number Publication date
EP0631504A1 (en) 1995-01-04
AU3888793A (en) 1993-10-21
KR950700754A (ko) 1995-02-20
WO1993018785A1 (en) 1993-09-30
JPH07504669A (ja) 1995-05-25

Similar Documents

Publication Publication Date Title
DK36492D0 (da) Praeparat
DE59303358D1 (de) Quaterrylentetracarbonsäureimide
DE59306810D1 (de) Gutbettwalzenmühle
DE59302851D1 (de) Sportschuh
BR9305745A (pt) Quebra-luz
DE59301902D1 (de) Kassenlade
DE59305364D1 (de) Rotornut
DE59304139D1 (de) Polyanile
BR9301712A (pt) Aplainador
ATA227792A (de) Sportschuh
DE59301762D1 (de) Chlorethylsulfonylbenzaldehyde
DK59092D0 (da) Praeparat
SK964U (sk) Komplexný fytogeriatrický preparát
DE59206388D1 (de) Kabeleckkanal
BR9200298A (pt) Microsisten-telesupervisao
BR9202793A (pt) Portimetro
BR7201859U (pt) Cambao
BR7202026U (pt) Aero-mala
BR9200231A (pt) Agrupador
BR9200295A (pt) Aurissima
BR9200296A (pt) Varre-lava
BR7200879U (pt) Cocho saleiro biazi
BR9200554A (pt) Lixoduto
BR9200611A (pt) Hidrocofre
BR9201140A (pt) Tarara batedora

Legal Events

Date Code Title Description
ATS Application withdrawn